CpG ODN 1826

CpG ODN 1826 is a synthetic 20-base single-stranded DNA oligonucleotide containing unmethylated CpG dinucleotides, which mimic microbial DNA and robustly activate the innate immune system in mice via Toll-like receptor 9 (TLR9)[1][3][7]. It acts as a **Type B (Class B) CpG oligodeoxynucleotide**, specifically designed as an immunostimulant and vaccine adjuvant in preclinical models. CpG ODN 1826 is a potent inducer of Th1-skewed immune responses, promoting B cell proliferation, immunoglobulin production, and induction of cytokines such as IL-6, IL-12, IFN-α, and IFN-γ in B cells, monocytes/macrophages, dendritic cells, and NK cells[4][5]. In mouse models, it enhances both innate and adaptive immune responses, has anti-tumor efficacy, and improves outcomes after trauma-hemorrhage through TLR9-mediated immunomodulation[1][2][4][7]. CpG ODN 1826 has shown strong adjuvant effects in murine vaccine experiments, reversal of immunosuppression in tumor-bearing animals, and potentiation of radiotherapy against diverse tumor types by enhancing tumor immunogenicity and fostering systemic memory T-cell responses[2][4][5][7]. Its sequence is 5'-tccatgacgttcctgacgtt-3'. It is not approved for human or veterinary clinical use and is primarily used in research and preclinical studies, especially in murine models[3].

Other names

CpG-ODN 1826CpG-ODN1826CpG-ODN-1826CpG ODN 1826